Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Sold by Marshall Wace LLP

Marshall Wace LLP lessened its position in Ikena Oncology, Inc. (NASDAQ:IKNA) by 49.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 44,933 shares of the company’s stock after selling 43,758 shares during the quarter. Marshall Wace LLP’s holdings in Ikena Oncology were worth $74,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. grew its stake in shares of Ikena Oncology by 813.7% in the 1st quarter. Jacobs Levy Equity Management Inc. now owns 513,440 shares of the company’s stock valued at $729,000 after purchasing an additional 457,245 shares during the last quarter. Acadian Asset Management LLC boosted its stake in shares of Ikena Oncology by 1,201.8% in the first quarter. Acadian Asset Management LLC now owns 282,782 shares of the company’s stock valued at $400,000 after buying an additional 261,060 shares in the last quarter. BBR Partners LLC purchased a new stake in shares of Ikena Oncology in the second quarter valued at approximately $33,000. Vanguard Personalized Indexing Management LLC acquired a new position in Ikena Oncology during the second quarter worth $30,000. Finally, Sofinnova Investments Inc. raised its holdings in Ikena Oncology by 230.7% during the second quarter. Sofinnova Investments Inc. now owns 382,616 shares of the company’s stock worth $631,000 after purchasing an additional 266,904 shares during the last quarter. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Ikena Oncology in a report on Monday, August 12th.

Ikena Oncology Stock Performance

IKNA stock opened at $1.72 on Monday. The stock has a 50-day moving average price of $1.70 and a two-hundred day moving average price of $1.58. Ikena Oncology, Inc. has a 12-month low of $1.02 and a 12-month high of $4.63. The company has a market cap of $83.00 million, a PE ratio of -1.09 and a beta of 0.49.

Ikena Oncology (NASDAQ:IKNA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.04. Equities analysts forecast that Ikena Oncology, Inc. will post -1.03 EPS for the current fiscal year.

Ikena Oncology Profile

Ikena Oncology, Inc operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.